Digital & Innovation
Novartis buys Amblyotech to develop novel digital therapy for ‘lazy eye’

Digital & Innovations: Novartis completed the acquisition of Amblyotech, a software startup, and will pursue the development of the acquired digital technology for the treatment of amblyopia (lazy eye).
The condition can lead to poor vision and other quality of life issues if left untreated. The condition can impact children and adults beyond their vision, making it difficult to drive and maintain a sense of autonomy. Current treatment options, including patching and/or atropine, are associated with low compliance and low success rates. Approved therapies for adults are limited.
Designed to enhance compliance, Amblyotech utilises active gaming and passive video technology with 3-D glasses, training the eyes to work together to view an image in full. Its software employs a unique visual presentation, called dichoptic display, where each eye is presented with different images using a proprietary algorithm. In early clinical studies, Amblyotech’s software demonstrated improvements in vision in both children and adults with faster onset compared to standard of care treatments.
HCP engagement during COVID-19. Fill the gap of reduced field force activities. Health Industry Hub combines expertise in delivering digital health content with high engagement and 20+ years industry experience. By industry for industry. Contact us.
“By offering a non-invasive solution that has the potential to be significantly faster than current standards of care such as patching for children and adults impacted by lazy eye, Amblyotech’s software is a great example of how we can reimagine medicine using digital technology,” said Nikos Tripodis, Global Business Franchise Head, Ophthalmology.
With the transaction closing, Novartis plans to work in partnership with video game developer, Ubisoft, to develop the Amblyotech software as a medical device (SaMD), create a series of engaging games for the device, and conduct a proof of concept study (PoC), planned for later in 2020.
Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
News & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
MoreNews & Trends - Pharmaceuticals

AI-powered test to reshape use of hormone therapy in prostate cancer
Australian researchers are pioneering the use of artificial intelligence (AI) to enhance decision-making in prostate cancer treatment, specifically focusing on […]
MoreNews & Trends - MedTech & Diagnostics

Vantive debuts as standalone business amid complex landscape of chronic kidney disease
Vantive, formerly Baxter’s Kidney Care business, has officially launched as a standalone company. The move follows Baxter’s completion of the […]
MoreNews & Trends - MedTech & Diagnostics

Optalert unveils test for sleep apnoea as Philips expands partnership in pharmacy program
An Australian medical technology company has introduced a test designed to identify obstructive sleep apnoea (OSA), broadening access to sleep […]
More